PubHawk
J Immunother Cancer December 2022 PMID 36564126

Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study.

Brendan D Curti, Jon Richards, John R Hyngstrom, Gregory A Daniels, Mark Faries, Lynn Feun, Kim A Margolin, Sigrun Hallmeyer, Mark Grose, Yiwei Zhang, Anlong Li, Robert H I Andtbacka

Download social card

Mentions

16
Peak: 7 in Dec 2022
across 2 sources since Dec 2022

Extended reach

34,589
potential audience

Total likes

48

Video views

384

Mentions per month

Dec 2022 – Feb 2023

Where it's discussed

  • X / Twitter15 posts
  • YouTube1 videos

AI synopsis

What people are saying

The discussions reflect a positive reception, with posts describing the study as 'promising' and 'leading,' and emphasizing its potential impact on melanoma treatment. The tone and choice of words like 'advancing therapy' and 'phase 1b study' demonstrate genuine interest and engagement, while also recognizing the study’s significance within cancer research.

AgreementModerate agreement

Most posts recognize the positive outcomes of the study, highlighting its promising results, indicating general agreement.

InterestModerate interest

Discussions show moderate interest, with many posts emphasizing the innovative nature of the treatment and its potential significance.

EngagementModerate engagement

Participants refer to specifics like tumor regression and the study's methodology, reflecting thoughtful engagement.

ImpactModerate impact

Posts suggest the study could influence future melanoma treatments and spark further research, indicating a moderate to high impact.

Abstract in brief

  • The study investigates the safety and effectiveness of combining intratumoral V937, a genetically unmodified coxsackievirus A21, with the immune checkpoint inhibitor ipilimumab in treating advanced melanoma, showing a promising objective response rate of 30% overall.
  • Patients received multiple intratumoral injections of V937 along with intravenous ipilimumab, with tumor regression observed in both injected and non-injected lesions, and a median progression-free survival of approximately 6.2 months.
  • The treatment was generally well tolerated, with common side effects like pruritus, fatigue, and diarrhea, and no dose-limiting toxicities related to V937 were reported.]
Read the full abstract

Top posts

Most liked on X and Bluesky
Journal for ImmunoTherapy of Cancer
@jitcancer · X

New #JITC article: Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study https://t.co/oK4ockCNak @BrendanCurtiMD @RobertAndtbacka https://t.co/QW4YFpKgVY

Dec 26, 2022 · 15 likes · 1 share · 9,359 followers View post →
星良孝 Yoshitaka Hoshi
@yoshitakahoshi · X

進行悪性黒色腫に対してウイルス療法と免疫チェックポイント阻害薬を組み合わせて治療したところ奏効率3割という結果。 https://t.co/2Sjqbi2cjY

Jan 9, 2023 · 8 likes · 3 shares · 8,184 followers View post →
R. Bryan Bell, MD, DDS, FACS, FRCS(Ed)
@rbryanbell · X

Congratulations to our own @BrendanCurtiMD @ChilesResearch for leading this promising phase 1b MITCI study of intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma. https://t.co/yNVOYiqsKz @providence @Merck @jitcancer

Dec 27, 2022 · 7 likes · 3 shares · 2,529 followers View post →
Earle A. Chiles Research Institute
@ChilesResearch · X

ICYMI via @jitcancer: Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced #melanoma: the phase 1b MITCI study from @BrendanCurtiMD and colleagues. https://t.co/J4SwDKYHuy

Feb 6, 2023 · 2 likes · 2 shares · 1,541 followers View post →
Δt
@zimei_no_ri · X

RT @yoshitakahoshi: 進行悪性黒色腫に対してウイルス療法と免疫チェックポイント阻害薬を組み合わせて治療したところ奏効率3割という結果。 https://t.co/2Sjqbi2cjY

Jan 10, 2023 · 3 shares · 3,638 followers View post →
R. Bryan Bell, MD, DDS, FACS, FRCS(Ed)
@rbryanbell · X

RT @ChilesResearch: ICYMI via @jitcancer: Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced #melanoma: the phase…

Feb 6, 2023 · 2 shares · 2,529 followers View post →

All mentions

Providence Swedish Cancer Institute Research
@ProvSwedCancRes · X

RT @ChilesResearch: ICYMI via @jitcancer: Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced #melanoma: the phase…

Feb 6, 2023 · 2 shares · 96 followers View post →
R. Bryan Bell, MD, DDS, FACS, FRCS(Ed)
@rbryanbell · X

RT @ChilesResearch: ICYMI via @jitcancer: Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced #melanoma: the phase…

Feb 6, 2023 · 2 shares · 2,529 followers View post →
Earle A. Chiles Research Institute
@ChilesResearch · X

ICYMI via @jitcancer: Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced #melanoma: the phase 1b MITCI study from @BrendanCurtiMD and colleagues. https://t.co/J4SwDKYHuy

Feb 6, 2023 · 2 likes · 2 shares · 1,541 followers View post →
STELLANEWS.LIFE
@stellanewslife · X

RT @yoshitakahoshi: 進行悪性黒色腫に対してウイルス療法と免疫チェックポイント阻害薬を組み合わせて治療したところ奏効率3割という結果。 https://t.co/2Sjqbi2cjY

Jan 11, 2023 · 3 shares · 812 followers View post →
Δt
@zimei_no_ri · X

RT @yoshitakahoshi: 進行悪性黒色腫に対してウイルス療法と免疫チェックポイント阻害薬を組み合わせて治療したところ奏効率3割という結果。 https://t.co/2Sjqbi2cjY

Jan 10, 2023 · 3 shares · 3,638 followers View post →
Thomas Trust Thompson
@Akouqi · X

RT @yoshitakahoshi: 進行悪性黒色腫に対してウイルス療法と免疫チェックポイント阻害薬を組み合わせて治療したところ奏効率3割という結果。 https://t.co/2Sjqbi2cjY

Jan 9, 2023 · 3 shares · 162 followers View post →
星良孝 Yoshitaka Hoshi
@yoshitakahoshi · X

進行悪性黒色腫に対してウイルス療法と免疫チェックポイント阻害薬を組み合わせて治療したところ奏効率3割という結果。 https://t.co/2Sjqbi2cjY

Jan 9, 2023 · 8 likes · 3 shares · 8,184 followers View post →
Earle A. Chiles Research Institute
@ChilesResearch · X

RT @rbryanbell: Congratulations to our own @BrendanCurtiMD @ChilesResearch for leading this promising phase 1b MITCI study of intratumoral…

Jan 3, 2023 · 3 shares · 1,541 followers View post →
Hagen Kennecke
@HKennecke · X

RT @rbryanbell: Congratulations to our own @BrendanCurtiMD @ChilesResearch for leading this promising phase 1b MITCI study of intratumoral…

Dec 27, 2022 · 3 shares · 1,379 followers View post →
Shay Sharon, DMD, MD, PhD
@ShaySharonOMFS · X

RT @rbryanbell: Congratulations to our own @BrendanCurtiMD @ChilesResearch for leading this promising phase 1b MITCI study of intratumoral…

Dec 27, 2022 · 3 shares · 154 followers View post →
R. Bryan Bell, MD, DDS, FACS, FRCS(Ed)
@rbryanbell · X

Congratulations to our own @BrendanCurtiMD @ChilesResearch for leading this promising phase 1b MITCI study of intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma. https://t.co/yNVOYiqsKz @providence @Merck @jitcancer

Dec 27, 2022 · 7 likes · 3 shares · 2,529 followers View post →
Enrique Sanz-Garcia
@Esanzgarcia · X

RT @jitcancer: New #JITC article: Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI…

Dec 26, 2022 · 1 share · 392 followers View post →
Journal for ImmunoTherapy of Cancer
@jitcancer · X

New #JITC article: Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study https://t.co/oK4ockCNak @BrendanCurtiMD @RobertAndtbacka https://t.co/QW4YFpKgVY

Dec 26, 2022 · 15 likes · 1 share · 9,359 followers View post →
UofU3i
@UofU3i · X

New 3i Investigator Article Alert!! Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study https://t.co/AcCOsLFCPs

Dec 25, 2022 · 1,179 followers View post →
Phage Papers
@Phage_Papers · X

Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study https://t.co/rbYwGruCEb

Dec 24, 2022 · 646 followers View post →